Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 4/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3663221 | 0.98 | POLB (0.54) | POLBHTTL3MBTL1NPC1CYP3A4 | |
| SCHEMBL1953578 | 0.91 | POLB (0.61) | POLBHTTL3MBTL1NPC1CYP3A4 | |
| SCHEMBL31151974 | 0.90 | POLB (0.43) | POLBHTTL3MBTL1NPC1CYP3A4 | |
| SCHEMBL31152002 | 0.89 | POLB (0.44) | POLBHTTL3MBTL1NPC1CYP3A4 | |
| SCHEMBL19426395 | 0.85 | POLB (0.56) | POLBHTTL3MBTL1NPC1CYP3A4 | |
| SCHEMBL1783172 | 0.85 | MEN1 (0.52) | LMNAMAPTMEN1KMT2AALDH1A1 | |
| SCHEMBL8094959 | 0.84 | LMNA (0.48) | POLBHTTL3MBTL1NPC1CYP3A4 | |
| SCHEMBL2899450 | 0.83 | POLB (0.52) | POLBHTTL3MBTL1NPC1CYP3A4 | |
| SCHEMBL2610744 | 0.82 | POLB (0.56) | POLBHTTL3MBTL1NPC1CYP3A4 | |
| SCHEMBL6383566 | 0.81 | HTT (0.59) | POLBHTTL3MBTL1NPC1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080039473-A1 | PREPARATION AND UTILITY OF SUBSTITUTED QUINAZOLINE COMPOUNDS WITH ALPHA-ADRENERGIC BLOCKING EFFECTS | AUSPEX PHARMACEUTICALS, INC. (US) | 2008-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080039473-A1 | PREPARATION AND UTILITY OF SUBSTITUTED QUINAZOLINE COMPOUNDS WITH ALPHA-ADRENERGIC BLOCKING EFFECTS | ADRB1, ADRB2, ADRB3 | POLB 2328/4885HTT 4597/4885L3MBTL1 3670/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.